Gastrinoma in multiple endocrine neoplasia type 1 after total pancreatectomy

A case report

Shu Gong, MSa, Zhi Li, MSa, Xu-Bao Liu, MD, PhDa, Xin Wang, MD, PhDb, Wen-Wu Shen, MDc,∗

Abstract

Rationale: Surgery for patients with multiple endocrine neoplasia type 1 (MEN-1) related gastrinoma remains controversial and total pancreatectomy (TP) has rarely been performed. We reported a case of patient with MEN-1 related gastrinoma treated by TP.

Patient concerns: A 46-year-old female was admitted to our hospital due to abdominal distension and diarrhea for 2 years. The patient underwent pituitary tumor resection and kidney stone lithotripsy 10 years ago.

Diagnoses: Abdominal computed tomography showed single lesion in the duodenum and multiple lesions throughout the pancreas. The patient’s gastrin level was significantly increased (1080 pg/ml). These findings in combination with the pituitary tumor history suggested the presence of gastrinoma associated with MEN-1 syndrome.

Intervention: An exploratory laparotomy was performed. Intraoperative ultrasound confirmed the numerous tumors diffusely distributed throughout the pancreas and the patient eventually underwent TP.

Outcomes: Twelve months later, the patient was hospitalized again for anastomotic fistula and underwent a partial gastrectomy, small bowel resection and drainage of the abscess. One month later, she received gastrostomy and jejunostomy due to digestive tract fistula, and died a month later (14 months after TP).

Lessons: There still might be the possibility of recurrence even after radical surgical resection of gastrinomas, and we suggest the need to measure the basal acid output and maintain regular anti-acid therapy in the long-term follow-up of patients with MEN-1 related gastrinoma.

Abbreviations: CT = computed tomography, MEN-1 = multiple endocrine neoplasia type 1, MRI = magnetic resonance imaging, pNET = pancreatic neuroendocrine tumor, PPIs = proton pump inhibitors, TP = total pancreatectomy.

Keywords: gastrinoma, MEN-1, total pancreatectomy

1. Introduction

Gastrinoma is the second most common functional pancreatic neuroendocrine tumor (pNET), with a yearly incidence of approximately 0.5 to 21.5 cases per a million of people worldwide.[1] Gastrinomas are located predominantly in the duodenum (70%) and pancreas (25%).[1] They are characterized by gastric hypersecretion that results in peptic ulcers and diarrhea; this condition is known as Zollinger–Ellison syndrome (ZES).[1–4] Most gastrinomas are sporadic (75%–80%), whereas approximately 20% to 25% are associated with multiple endocrine neoplasia type 1 (MEN-1).[1] In patients with MEN-1, tumors are generally small, multiple and have a high tendency to metastasize; thus, achieving biochemical cure without radical surgical resection is impossible.[6–7] However, surgery for patients with MEN-1 remains controversial because of its potential short- and long-term complications,[6–7] and a total pancreatectomy (TP) has rarely been performed. Here, we reported a case of a patient with MEN-1 associated gastrinoma treated by TP.

2. Case presentation

A 46-year-old female was admitted to our hospital complaining of abdominal distension and diarrhea for 2 years. Gastroscopy revealed duodenal ulcer, and she was treated with proton pump inhibitors (PPIs) for half a year, but symptoms persisted. The patient underwent pituitary tumor resection and kidney stone lithotripsy 10 years ago. The patient’s gastrin level was significantly elevated (1080 pg/ml; normal range: 5–100 pg/ml). Parathyroid hormone, blood calcium, and serum tumor markers (AFP, CEA, CA 19–9, and CA 125) were normal. Abdominal computed tomography (CT) showed one local thickening of descending duodenum wall and several lesions located in the head, body, and tail of pancreas, and the largest one, which measured 0.8 cm × 0.6 cm, was located in the pancreatic head
These findings in combination with the pituitary tumor history suggested the presence of gastrinoma associated with MEN-1 syndrome.

An exploratory laparotomy was performed. In surgery, several tumors were found in the head, body, and tail of pancreas; furthermore, a tumor without well-defined boarders was palpable in the duodenum (Fig. 2). Intraoperative ultrasound confirmed that numerous tumors were diffusely distributed throughout the pancreas. The patient eventually underwent TP with peripancreatic lymph node resection.

Pathology confirmed a multifocal neuroendocrine neoplasm, of which 1 gray solid nodule measuring 1 cm × 0.5 cm × 0.5 cm was found in the submucosa of the descending duodenum; 12 gray solid nodules were found in the head, body, and tail of the pancreas, ranging from 0.3 cm to 0.8 cm in diameter. Additionally, one was classified as grade 2 (Ki-67 index, 3%–5%), and the others were grade 1 (Ki-67 index, <2%) according to the World Health Organization 2010 classification system. Immunohistochemical analysis results revealed that the tumor cells were positive for Syn, CgA, and gastrin (Fig. 3). Moreover, two metastatic peripancreatic lymph nodes were identified (Ki-67 index, <2%).

Postoperative gastrin level decreased to 23.25 pg/ml. The patient recovered uneventfully and was discharged 7 days after surgery. After discharge, the patient persisted regular follow-up in endocrine clinic and had a stable control of blood glucose. Twelve months later, she was hospitalized for progressive abdominal pain with fullness and fever. The gastrin level was almost within normal limits (125 pg/ml). CT scan revealed encapsulated effusion and gases surrounding the gastrointestinal anastomosis (Fig. 4), thereby suggesting an anastomatic fistula. Then, a laparotomy was performed again, and a huge abscess measuring 5 cm × 10 cm was found around the anastomosis. The patient underwent partial gastrectomy, small bowel resection, and drainage of the abscess. One month later, the patient was hospitalized again for digestive tract fistula. Gastrostomy and jejunostomy were performed, and the patient died for severe malnutrition 1 month later (14 months after TP).

Informed consent was obtained from the patient’s son for this publication and any accompanying images.

3. Discussion

MEN-1 is a rare, autosomal dominant inherited syndrome caused by mutations in the MEN-1 tumor suppressor gene. Patients can be diagnosed with MEN-1 when 2 or more primary endocrine tumors, including pituitary tumors, pancreatic tumors, and parathyroid adenomas, associated with MEN-1 are present. The incidence of MEN-1 is 0.25% and 16% to 38% in patients with gastrinomas. In patients with MEN-1 associated gastrinomas, the average onset is 5 to 10 years earlier than that of sporadic gastrinomas and generally before 50 years old. Gastrinomas in patients with MEN-1 mostly occur in the duodenum (85%–100%) and less commonly in the pancreas (0%–15%); the tumors are often multiple and small (<0.5 cm) and are associated with lymph node metastases in 40% to 60% of patients.
In our case, interestingly, tumors were mainly located in the pancreas. The most common presenting symptoms of gastrinomas include abdominal pain, diarrhea, and esophageal symptoms. The diagnostic evaluation of gastrinomas begins by measuring a fasting serum concentration of gastrin. If the fasting serum gastrin is more than 10-fold normal (<100 pg/ml) and the gastric pH is < 2, a diagnosis of gastrinoma is established. Ultrasonography, CT, MRI, somatostatin receptor scintigraphy, and endoscopic ultrasonography are useful and important modalities for localization diagnosis and ruling out metastases.

Surgery for patients with MEN-1 associated gastrinomas remains controversial. Several authors conclude that the multicentricity of tumors mostly in the duodenum preclude surgical cure and suggest medical therapy, such as PPIs and/or somatostatin analogs. Others recommend surgical resection of tumors only if the tumor is larger than 2 to 3 cm, and enucleation at surgery remains the generally recommended surgical procedure. However, larger tumors are often associated with increased metastatic risk and, consequently, reduced curability. Some surgeons support a more aggressive surgery, such as pancreas-preserving total duodenectomy, Whipple pancreaticoduodenectomy, or TP, to reduce the risk of distant metastases, achieve biochemical cure, and improve survival.

There is a general agreement that TP should be avoided, except in cases of multiple and diffuse macroscopic lesions. To date, TP has rarely been performed for patients with MEN-1. We searched literature and found only 3 cases of MEN-1 receiving TP as initial surgery because of the diffuse presence of macroscopic tumors within the pancreas; furthermore, 3 cases had TP at reoperation, of which TP in one case was as a rescue after the dehiscence of pancreato-jejunal anastomosis. However, the long-term survival of the above cases had been seldom reported. In our case, the patient died 14 months later from serious infection and severe malnutrition caused by the disruption of gastrointestinal anastomosis. The reason why the anastomotic fistula occurred 12 months after TP was unclear. Hypersecretion of gastric acid persists in up to 62% of the patients with gastrinomas after surgical excision of tumors; hence, maintaining a postoperative anti-acid therapy is necessary. Ulcer perforation caused by the hypersecretion of gastric acid might be the cause of the rupture of gastrointestinal anastomosis.

4. Conclusion

We reported a case of patient diagnosed with MEN-1 associated gastrinoma and died 14 months after TP. Hypersecretion of gastric acid may persist in patients after complete removal of tumors, and we suggest the need to measure the basal acid output and maintain regular anti-acid therapy in a long-term follow-up, considering the possibility of recurrence even after radical surgical resection.

Author contributions

Supervision: Xu-Bao Liu, Wen Wu Shen.
Writing – original draft: Shu Gong, Zhi Li.
Writing – review & editing: Xin Wang, Wen Wu Shen.

References

[1] Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 2016;103:153–71.
[2] Roy PK, Venzon DJ, Shoamanesh H, et al. Zollinger-Ellison syndrome: Clinical presentation in 261 patients. Medicine (Baltimore) 2000;79:379–411.
[3] Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009;46:13–06.
[4] Norton JA, Foster DS, Ito T, et al. Gastrinomas: medical or surgical treatment. Endocrinol Metab Clin North Am 2018;47:577–601.
[5] Krampitz GW, Norton JA. Current management of the Zollinger-Ellison syndrome. Adv Surg 2013;47:39–79.
[6] Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004;240:757–73.
[7] Epelboym I, Mazeh H. Zollinger-Ellison syndrome: classical considerations and current controversies. Oncologist 2014;19:44–50.

[8] Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012;97:2990–3011.

[9] Ito T, Igarashi H, Uehara H, et al. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study; comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore) 2013;92:135–81.

[10] Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006;243:265–72.

[11] Mulvey CK, Van Loon K, Bergsland EK, et al. Complicated case presentation: management of pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. Pancreas 2017;46:416–26.

[12] Mendelson AH, Donowitz M. Catching the Zebra. Clinical pearls and pitfalls for the successful diagnosis of Zollinger-Ellison syndrome. Dig Dis Sci 2017;62:2258–65.

[13] Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853–8.

[14] Mignon M, Ruszniewski P, Podevin P, et al. Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type 1. World J Surg 1993;17:489–97.

[15] Lips CJ. Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. J Intern Med 1998;243:589–94.

[16] Norton JA, Jensen RT. Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg 2009;205(Suppl 4):S34–7.

[17] Gibril F, Venon DJ, Ojeaburu JV, et al. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 2001;86:3282–93.

[18] Imamura M, Komoto I, Ota S, et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 2011;17:1343–53.

[19] Bartsch DK, Fendrich V, Langer P, et al. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2005;242:757–64.

[20] Tonelli F, Fratini G, Nesi G, et al. Pancreatectomy in multiple endocrine neoplasia Type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 2006;244:61–70.

[21] Tisel LE, Ahlman H, Jansson S, et al. Total pancreatectomy in the MEN-1 syndrome. Br J Surg 1998;75:154–7.

[22] Norton JA, Krampitz GW, Poulsides GA, et al. Prospective evaluation of results of reoperation in Zollinger-Ellison Syndrome. Ann Surg 2018;267:782–8.

[23] Ojeaburu JV, Ito T, Crafa P, et al. Mechanism of acid hypersecretion post curative gastrinoma resection. Dig Dis Sci 2011;56:139–54.